Outcome and prognosis for canine appendicular osteosarcoma treated with stereotactic body radiation therapy in 123 dogs. (13th January 2021)

• Record Type: Journal Article
• Authors: Martin, Tiffany Wormhoudt; Griffin, Lynn; Custis, James; Ryan, Stewart D.; Lafferty, Mary; Boss, Mary‐Keara; Regan, Daniel; Rao, Sangeeta; Leary, Del; Withrow, Stephen J.; LaRue, Susan M.
• Is Part Of: Veterinary and comparative oncology. Volume 19:Number 2(2021)
• Page Start: 284
• Page End: 294
• Publication Date: 2021-01-13
• Subjects: bone -- lameness -- limb‐spare -- radiotherapy -- stereotactic; Veterinary oncology -- Periodicals; Neoplasms -- veterinary -- Periodicals; 636.0896994005
• DOI: 10.1111/vco.12674
• Languages: English
• ISSNs: 1476-5810

Abstract

Abstract: Canine appendicular osteosarcoma is commonly treated with limb amputation; however, limb‐sparing options are frequently desired or necessary for a subset of patients. We evaluated 123 patients and 130 sites treated with stereotactic body radiation therapy (SBRT). Eighty‐two out of 98 dogs (84%) had maximum lameness improvement at a median of 3 weeks for a median of 6 months duration. Histopathologic evaluation of available samples from amputation or necropsy revealed >80% tumor necrosis in 50% of limbs consistent with local disease control. Of evaluable patients, 41% fractured and 21% pursued an amputation after treatment. Fine needle aspirate (n = 52) and needle core biopsy (n = 28) did not result in increased fracture risk compared to those without tumor sampling (n = 50). Median survival time (MST) was 233 days and time to first event was 143 days. Gross tumor volume and planned target volume were significantly inversely associated with survival and tumor location was significantly associated with survival. Dogs with salvage amputation had a significantly longer MST compared to those without (346 vs 202 days; P = .04). The presence of metastatic disease at the time of treatment in 15 dogs did not significantly impact survival time (200 vs 237 days without metastasis; P = .58). Skin side effects correlated significantly with dose with 33% of patients with acute grade 3 effects developing consequential late grade 3 effects. While SBRT improves lameness in most patients, further investigation is needed to identify candidates with minimal early fracture risk prior to initiating therapy.